{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:25:32Z","timestamp":1795026332951,"version":"4.10.2"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Chemosensitivity and radiosensitivity are associated with the prognosis of colorectal cancer, and the expression of the ataxia-telangiectasia mutated (ATM) protein plays an essential role in these processes. The present study examined the relationship between ATM expression and the survival outcomes of colorectal cancer patients and explored the underlying mechanism and promising therapeutic strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A search including medical subject headings (MeSH), free terms, and combined words was conducted using Pubmed, EMBASE, and Cochrane. Studies had to meet the inclusion criteria as well as include processes such as data extraction and quality evaluation. The survival outcomes were assessed using hazard ratio (HR) and 95% confidence interval (CI). Heterogeneity, and publication bias were analyzed, and a P value &amp;lt;0.05 was considered statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine studies with 2883 patients were included in the meta-analysis. Low ATM expression level was related to poor overall survival (HR=0.542, 95% CI=0.447\u20130.637; P=0.000). Disease-free, progression-free, and recurrence-free survival rates were lower in patients with low ATM expression than in those with high ATM expression. There was no significant difference between Stage I\u2013II and Stage III\u2013IV colorectal cancer patients [risk ratio (RR)=1.173, 95% CI=0.970\u20131.417, P=0.690].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Low ATM expression level may be a marker of poor survival in colorectal cancer and contributes to resistance to therapy. Targeting related factors in these pathways to sensitize tumors to treatment is a potential therapeutic strategy, and monitoring ATM status could be a valuable guide independent of the immunotherapy or chemotherapy strategy used.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1470939","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:18:32Z","timestamp":1741756712000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["ATM is associated with the prognosis of colorectal cancer: a systematic review"],"prefix":"10.3389","volume":"15","author":[{"given":"Pei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jncc.2020.12.001","article-title":"Cancer incidence and mortality in China, 2015","volume":"1","author":"Zhang","year":"2021","journal-title":"J Natl Cancer Center"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0041","article-title":"Nccn guidelines\u00ae Insights: rectal cancer, version 3.2024","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4643","article-title":"Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: A nonrandomized phase 2 clinical trial","volume":"6","author":"Hayashi","year":"2020","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.577968","article-title":"Genetic variants in DNA repair pathways as potential biomarkers in predicting treatment outcome of intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: A systematic review","volume":"11","author":"Hulshof","year":"2020","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.027","article-title":"The DNA damage\u00a0response pathway as a land of therapeutic opportunities for colorectal cancer","volume":"31","author":"Mauri","year":"2020","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.05.011","article-title":"Ataxia telangiectasia mutated protein loss and benefit from oxaliplatin-based chemotherapy in colorectal cancer","volume":"17","author":"Sundar","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0047","article-title":"Nccn guidelines\u00ae Insights: colorectal cancer screening, version 1.2024","volume":"22","author":"Ness","year":"2024","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-05-2105","article-title":"Expression of DNA double-strand break repair proteins Atm and Brca1 predicts survival in colorectal cancer","volume":"12","author":"Grabsch","year":"2006","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"13455","DOI":"10.1038\/s41598-019-49878-4","article-title":"Tumor infiltrating lymphocytes and macrophages improve survival in microsatellite unstable colorectal cancer","volume":"9","author":"Narayanan","year":"2019","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S67814","article-title":"Downregulated Ku70 and ATM associated to poor prognosis in colorectal cancer among chinese patients","volume":"7","author":"Lu","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41598-019-39525-3","article-title":"Prognostic impact of ATM mutations in patients with metastatic colorectal cancer","volume":"9","author":"Randon","year":"2019","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12885-021-07926-1","article-title":"Sequential and co-occurring DNA damage response genetic mutations impact survival in stage iii colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605134","article-title":"Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array","volume":"101","author":"Kweekel","year":"2009","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000507118","article-title":"Genomic profiling of stage II colorectal cancer identifies candidate genes associated with recurrence-free survival, tumor location, and differentiation grade","volume":"98","author":"Dimberg","year":"2020","journal-title":"Oncology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.694","article-title":"Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN","volume":"3","author":"Beggs","year":"2012","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.237","article-title":"Microsatellite instability in colorectal cancer-the stable evidence","volume":"7","author":"Vilar","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ctrv.2016.10.005","article-title":"The evolving role of microsatellite instability in colorectal cancer: A review","volume":"51","author":"Gelsomino","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00569-4","article-title":"Optimizing immunotherapy for colorectal cancer","volume":"19","author":"Ganesh","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202267","article-title":"The mutational pattern of homologous recombination-related (Hrr) genes in Chinese colon cancer and its relevance to immunotherapy responses","volume":"13","author":"Zhou","year":"2020","journal-title":"Aging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002336","article-title":"Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers","volume":"9","author":"Ying","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(18)30117-1","article-title":"Mutation burden and other molecular markers of prognosis in colorectal cancer treated\u00a0with curative intent: results from the Quasar 2 clinical trial and an Australian community-based series","volume":"3","author":"Domingo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.3390\/cancers14122933","article-title":"Deep sequencing of\u00a0early T stage colorectal cancers reveals disruption of homologous recombination repair in microsatellite stable tumours with high mutational burdens","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"Atm in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"Atm and Atr as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41419-019-1784-x","article-title":"Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53bp1 and Brca1 at the DNA break sites induced by oxaliplatin in colorectal cancer","volume":"10","author":"Hu","year":"2019","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-0247","article-title":"Biomarkers of response and resistance to DNA repair targeted therapies","volume":"22","author":"Stover","year":"2016","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i29.9775","article-title":"Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years","volume":"20","author":"Panczyk","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2021.09.008","article-title":"Targeting the ATM kinase to enhance the efficacy of radiotherapy and outcomes for cancer patients","volume":"32","author":"Garc\u00eda","year":"2022","journal-title":"Semin Radiat Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205485","article-title":"Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line","volume":"21","author":"Kim","year":"2002","journal-title":"Oncogene."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.12.015","article-title":"Dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer","volume":"357","author":"Chen","year":"2015","journal-title":"Cancer Lett"},{"key":"B36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1039\/d1nr03869a","article-title":"All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and Ros production as prostate cancer radiosensitizer for potential clinical translation","volume":"13","author":"Guo","year":"2021","journal-title":"Nanoscale"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-011520-104722","article-title":"Checkpoint responses to DNA double-strand breaks","volume":"89","author":"Waterman","year":"2020","journal-title":"Annu Rev Biochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2019.02.049","article-title":"P53 pathway is a major determinant in the radiosensitizing effect of palbociclib: implication in cancer therapy","volume":"451","author":"Fern\u00e1ndez-Aroca","year":"2019","journal-title":"Cancer Lett"},{"key":"B40","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tcb.2020.12.011","article-title":"P53 and tumor suppression: it takes a network","volume":"31","author":"Boutelle","year":"2021","journal-title":"Trends Cell Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant P53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The Atm protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/35103059","article-title":"Chk2 kinase\u2013a busy messenger","volume":"2","author":"Bartek","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4514","article-title":"Radiosensitization by irinotecan is attributed to G2\/M phase arrest, followed by enhanced apoptosis, probably through the Atm\/Chk\/Cdc25c\/Cdc2 pathway in P53-mutant colorectal cancer cells","volume":"53","author":"Wang","year":"2018","journal-title":"Int J Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and Cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3892\/ijo.2014.2693","article-title":"5\u2212Fu resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in P53\u2212Mutated colon cancer cells","volume":"46","author":"Akasaka","year":"2015","journal-title":"Int J Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-2936","article-title":"Functional analysis of the Atm-P53-P21 pathway in the Lrf Cll4 trial: blockade at the level of P21 is associated with short response duration","volume":"18","author":"Lin","year":"2012","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1053\/srao.2002.35250","article-title":"The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer","volume":"12","author":"Xia","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.049","article-title":"Ampk regulates metabolism and survival in response to ionizing radiation","volume":"99","author":"Zannella","year":"2011","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.03.005","article-title":"Ionizing radiation activates Amp-activated kinase (Ampk): A target for radiosensitization of human cancer cells","volume":"78","author":"Sanli","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e2009","DOI":"10.1371\/journal.pone.0002009","article-title":"Etoposide induces Atm-dependent mitochondrial biogenesis through Ampk activation","volume":"3","author":"Fu","year":"2008","journal-title":"PloS One"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.08.020","article-title":"Integrating old and new paradigms of G1\/S control","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjv015","article-title":"P53 deficiency-induced smad1 upregulation suppresses tumorigenesis and causes chemoresistance in colorectal cancers","volume":"7","author":"Ruan","year":"2015","journal-title":"J Mol Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2016.3629","article-title":"Deficiency of 53bp1 inhibits the radiosensitivity of colorectal cancer","volume":"49","author":"Xiao","year":"2016","journal-title":"Int J Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.10.034","article-title":"Loss of Atm\/Chk2\/P53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas","volume":"18","author":"Squatrito","year":"2010","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M808410200","article-title":"Atm-mediated transcriptional elevation of prion in response to copper-induced oxidative stress","volume":"284","author":"Qin","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2014.00055","article-title":"PrP(C) from stem cells to cancer","volume":"2","author":"Martin-Lanner\u00e9e","year":"2014","journal-title":"Front Cell Dev Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.3390\/ijms20205107","article-title":"Prion protein in glioblastoma multiforme","volume":"20","author":"Ryskalin","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20222","article-title":"The cellular prion protein beyond prion diseases","volume":"150","author":"Manni","year":"2020","journal-title":"Swiss Med Wkly."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01746-0","article-title":"Tumor resistance to radiotherapy is triggered by an Atm\/Tak1-dependent-increased expression of the cellular prion protein","volume":"40","author":"Bernardino-Sgherri","year":"2021","journal-title":"Oncogene"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-15-0945","article-title":"Atm mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nm1237","article-title":"Atm regulates target switching to escalating doses of radiation in the intestines","volume":"11","author":"Ch\u2019ang","year":"2005","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3390\/cancers11081204","article-title":"Maintenance Bez235 treatment prolongs the therapeutic effect of the combination of Bez235 and radiotherapy for colorectal cancer","volume":"11","author":"Chen","year":"2019","journal-title":"Cancers"},{"key":"B65","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.radonc.2011.10.023","article-title":"Combination of quercetin with\u00a0radiotherapy enhances tumor radiosensitivity in vitro and in vivo","volume":"104","author":"Lin","year":"2012","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the Atm inhibitor Azd1390 in humans-a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro-oncology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10637-022-01216-8","article-title":"Phase I trial of Atm inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors","volume":"40","author":"Waqar","year":"2022","journal-title":"Investigat New Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical Atm inhibitor Azd1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"key":"B69","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"New Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant\u00a0therapy for stage iii colon cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00715-8","article-title":"Targeted activation of ferroptosis in colorectal cancer via Lgr4 targeting overcomes acquired drug resistance","volume":"5","author":"Zheng","year":"2024","journal-title":"Nat Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg240","article-title":"Loss\u00a0of\u00a0Atm sensitises P53-deficient cells to topoisomerase poisons and antimetabolites","volume":"14","author":"Fedier","year":"2003","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3147","article-title":"Low expression levels of Atm may substitute for Chek2\/Tp53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer","volume":"14","author":"Knappskog","year":"2012","journal-title":"Breast Cancer Res: BCR"},{"key":"B75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13046-020-01811-8","article-title":"Vulnerability to low-dose combination of irinotecan and niraparib in Atm-mutated colorectal cancer","volume":"40","author":"Vitiello","year":"2021","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00003495-200059004-00003","article-title":"Clinical pharmacokinetics and administration of established platinum drugs","author":"O\u2019Dwyer","year":"2000","journal-title":"Drugs"},{"key":"B77","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1358\/dof.2012.37.11.1830167","article-title":"Progress in platinum-derived drug development","volume":"37","author":"Farrell","year":"2012","journal-title":"Drugs Future"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-0171","article-title":"Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer","volume":"20","author":"Zeng","year":"2014","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01968-2","article-title":"Wild-type Idh2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer","volume":"40","author":"Qiao","year":"2021","journal-title":"Oncogene"},{"key":"B80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.molonc.2013.09.004","article-title":"Mir-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating Atm kinase","volume":"8","author":"Zhou","year":"2014","journal-title":"Mol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.09.001","article-title":"Atm is required for the repair of oxaliplatin-induced DNA damage in colorectal cancer","volume":"17","author":"Bakkenist","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.321","article-title":"P38mapk is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance","volume":"31","author":"de-la-Cruz-Morcillo","year":"2012","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx035","article-title":"Genetic variants of DNA repair-related genes predict efficacy of Tas-102 in patients with refractory metastatic colorectal cancer","volume":"28","author":"Suenaga","year":"2017","journal-title":"Ann Oncol."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"Atm-deficient colorectal cancer cells are sensitive to the parp inhibitor olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Trans Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1470939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:18:35Z","timestamp":1741756715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1470939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":85,"alternative-id":["10.3389\/fonc.2025.1470939"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1470939","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1470939"}}